Join me this month for a two-part podcast series, featuring Marisa Co and Gaelan Ritter from Bristol Myers Squibb! When you have a system that has essentially locked-in and not seen much progress of late it requires a system-level rethink. That is the s…lnkd.in/e3wN7VZB

The power of the annual ISPOR—The Professional Society for Health Economics and Outcomes Research meetings is an emphasis on "decisions." The confidence to take decisions is hard to achieve. It is often the result of independent peer-reviewed research…lnkd.in/g_ecGTKY

Please join me and my co-authors @DRKKMCGI and Mike for view on how the confluence of technically enabled data access, data federation, and advanced computational sciences that will reshape Translational Sciences in oncology. This federated data at scale…lnkd.in/ez6RhGfC

Please join me in the latest The ConcertAI Podcast with Dr. Andrew Beck, M.D., the Co-founder and CEO of PathAI. The power of digital pathology is multi-fold in how it allows for rapid machine interpretation to augment human reads, identification of spec…lnkd.in/ecSN_wd3

We are excited to be at UKIO in two short weeks! UK Imaging and Oncology has emerged as one of the top venues in the UK for the last in advanced imaging solutions and clinical AI. ConcertAI is the leading oncology research and AI SaaS Solutions company,…lnkd.in/eQBX8bYq

Boston, and now Eastern New England, is the Hub for Biomedical R&D for a number of reasons. It has (1) the greatest density of academic centers at the intersection of technology, bench sciences and data sciences; (2) medical centers that are also researc…lnkd.in/eqAdC9gC

As a board and executive committee member, I am proud and excited for MassBio's announcement today of ‘Bioversity,’ a non-profit created to develop new training pathways and employer connections for underrepresented populations .…lnkd.in/e4e3gWXC bioversityma.org

Prostate cancer is devasting to men around the world. Solutions that provide AI-driven analyses improving the accuracy and speed of prostate cancer detection and diagnosis can make a significant contribution to outcomes. ConcertAI's TeraRecon, Inc. busi…lnkd.in/eEDkY5mv

Few things are as exciting as the American Society of Clinical Oncology (ASCO) annual meeting. It is a time for the latest in translational and clinical insights to advance at scale. The ConcertAI team has done wonderful work and has the privilege of nu…lnkd.in/g4rtYPyY

ConcertAI is deeply committed to health equity and trial diversity. All of our RWD and AI SaaS solutions integrate Social Determinants of Health and considerations of the populations most adversely impacted by specific cancers. Please reach out to info@…lnkd.in/guvVQtd9

The American Society of Clinical Oncology (ASCO) annual meeting is a remarkable event that shapes innovations, changes in the standard of care, and research priorities in the year that follows. We hope you will be able to attend our posted sessions featu…lnkd.in/gGsanzaY

Over the last several months, ConcertAI and Caris Life Sciences have collaborated on building research data sets of unprecedented depth, providing Translational and Clinical Development teams the ability to more deeply understand d…lnkd.in/ev2nrG_8 lnkd.in/e5GbbzZY

Over the last several months, ConcertAI and Caris Life Sciences have collaborated on building research data sets of unprecedented depth, providing Translational and Clinical Development teams the ability to more deeply understand diseases processes; bette…lnkd.in/eYEZyDCz

In oncology real-world evidence research, few things are as complex as Line of Therapy rules. I hope you take the opportunity to join my ConcertAI college Smita Agrawal's session on the derivation and enhancement of Line of Therapy through the integratio…lnkd.in/eHTcTqg4

We are so please to present ConcertAI's results from our Digital Trial Solution in two ASCO posters. These highlight the power of Generative AI and advanced AI Imputation methodologies that overcome the traditional limitations of real-world data and its…lnkd.in/eNykAeri

I had the pleasure of a session with George Sledge, CMO of Caris Life Sciences this morning. A provocative and future directed discussion on how high depth and population scale clinico-genomic datasets will change translational sciences, early phase clin…lnkd.in/eJi739V6

The 2023 American Society of Clinical Oncology (ASCO) was inspiring, humbling, and motivating. The advances shared were extraordinary -- paradigm shifting in the diagnosis and treatment of many cancers. The practical and remarkable application of LLM AI…lnkd.in/eEeaNMKK

My ConcertAI colleague, Dan McSweeney, head of our TeraRecon, Inc. Clinical AI and Interpretation Solution Suite for Radiology, had the opportunity to talk to Interventional Oncology Learning about promise of Clinical AI for supporting physician diagnoses…lnkd.in/eBQKdfZq

When I started to write this post, I had anticipated that I would focus on how bias has no place in clinical research or clinical care; that access and equity are consonant; and that we hold a responsibility to understand the unique healthcare needs of th…lnkd.in/eQDJb93e

As we close an exceptionally busy June, I wanted to reflect on the American Society of Clinical Oncology (ASCO) 2023 meeting and some of the advances and innovations presented and foretold. The theme of 'individualized precision oncology' pervaded many p…lnkd.in/eZwGxV9K